Wasatch Advisors’s BioAtla BCAB Stock Holding History

Wasatch Advisors’s Portfolio BCAB Stock Details BCAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-9,883	Closed	-$840K	–	251
2023 Q3	$840K	Sell	9,883 -20,136	-67%	-$2.57M	0.01%	244
2023 Q2	$4.5M	Buy	30,019 +4,656	+18%	+$801K	0.03%	212
2023 Q1	$3.4M	Buy	25,363 +13,783	+119%	+$2.48M	0.02%	221
2022 Q4	$4.78M	Buy	+11,580	New	+$4.8M	0.03%	201

Other funds holding BCAB

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wasatch Advisors's BCAB Position: Q4 2023 in Review

Wasatch Advisors sold out of BioAtla (BCAB) in Q4 2023, closing a stake of 9,883 shares — an estimated $840K sold.

Wasatch Advisors first reported a position in BCAB in Q4 2022 and held it in 4 quarters. The position peaked at $4.78M in Q4 2022. 79 funds tracked by Wall St. Rank hold BCAB as of Q4 2023.

Wasatch Advisors reported no remaining BioAtla position as of Q4 2023 after selling out during the quarter.
Wasatch Advisors sold 9,883 BioAtla shares in Q4 2023, an estimated $840K.
Wasatch Advisors first reported a position in BioAtla in Q4 2022 and held it in 4 quarters.
Wasatch Advisors's BioAtla position peaked at $4.78M in Q4 2022.
79 funds tracked by Wall St. Rank held BioAtla as of Q4 2023.

Based on Wasatch Advisors's 13F filing for Q4 2023, filed 14 Feb 2024.